Tempus AI Inc (NASDAQ: TEM ) stock is trading lower on Monday as the stock is pulling back from an approximately 20% surge over the last week.
Personalis Deal Draws Attention
The recent surge in the stock was driven by momentum from Phase 3 INTerpath-001 results from Merck & Co. Inc. (NYSE: MRK ) and Moderna Inc. (NASDAQ: MRNA ) of intismeran autogene (a custom mRNA neoantigen therapy) paired with Keytruda for advanced melanoma.
The data puts a spotlight on the company’s $1.5 billion Personalis Inc. (NASDAQ: PSNL ) deal.
Moderna uses Personalis’ sequencing platform to analyze tumor tissue and identify specific neoantigens needed to manufacture individualized doses.
Tempus AI Gets FDA Clearance For Pulmonary Hypertension Tool
On Monday, Tempus received FDA 510(k) clearance for ECG-PH, an AI product intended to detect signs of pulmonary hypertension from a standard ECG.
Read Next MarketsModerna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight
Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains on positive cancer trial results.
3 min read Read this articleThe clearance adds pulmonary hypertension to the company’s FDA-cleared AI products alongside atrial fibrillation and low ejection fraction .
Analyst Consensus & Recent Actions
The stock carries a Hold rating with an average price forecast of $61.27. Recent analyst moves include:
BTIG: Buy (Raises Forecast to $80.00) (August 20) Piper Sandler: Neutral (Lowers Forecast to $56.00) (August 4) BTIG: Buy (Lowers Forecast to $70.00) (August 3) Trending Get a 1% Match on Your First Deposit of $1,000+Top ETFs Holding Tempus AI (TEM)
ARK Innovation ETF (NYSE: ARKK ): 4.94% Weight ARK Genomic Revolution ETF (BATS: ARKG ): 6.86% Weight Wisdomtree BioRevolution Fund (NASDAQ: WDNA ): 2.52% WeightHow Tempus AI Ranks On Momentum Versus The Market
Below is the Benzinga Edge scorecard for Tempus AI, highlighting its strengths and weaknesses compared to the broader market:
Momentum: Bullish (Score: 83.09) — The stock is still screening as a momentum name despite today’s sharp pullback.The Verdict: Tempus AI’s Benzinga Edge signal reveals a momentum-driven story, with the scorecard emphasizing trend strength more than fundamentals.
For longer-term traders, that typically means risk management around support/resistance matters more than trying to “average” the move on volatile days.
TEM Stock Price Activity: Tempus AI shares were down 6.78% to $67.76 at the time of publication on Monday, according to Benzinga Pro data .
Read Next TechEU Tariffs Threaten Temu Margins After US Trade Squeeze
PDD says new EU tariffs will raise Temu's costs and slow cross-border orders as the company adapts after U.S. trade changes.
3 min read Read this articlePhoto courtesy: Piotr Swat via Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Trading Ideas Movers News FDA General Biotech Health Care Large Cap Why It's Moving benzai